Cargando…

Report of a germline double heterozygote in MSH2 and PALB2

BACKGROUND: Carriers with pathogenic variants in MSH2 have increased risk to develop colorectal, endometrium, ovarian, and other types of cancer. The PALB2 is associated with breast, ovarian, pancreatic, and prostate cancer. We describe the case of a 42‐year‐old female diagnosed with endometrial can...

Descripción completa

Detalles Bibliográficos
Autores principales: Agiannitopoulos, Konstantinos, Papadopoulou, Eirini, Tsaousis, Georgios N., Pepe, Georgia, Kampouri, Stavroula, Patsea, Eleni, Lypas, George, Nasioulas, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549547/
https://www.ncbi.nlm.nih.gov/pubmed/32853479
http://dx.doi.org/10.1002/mgg3.1242
_version_ 1783592814240595968
author Agiannitopoulos, Konstantinos
Papadopoulou, Eirini
Tsaousis, Georgios N.
Pepe, Georgia
Kampouri, Stavroula
Patsea, Eleni
Lypas, George
Nasioulas, George
author_facet Agiannitopoulos, Konstantinos
Papadopoulou, Eirini
Tsaousis, Georgios N.
Pepe, Georgia
Kampouri, Stavroula
Patsea, Eleni
Lypas, George
Nasioulas, George
author_sort Agiannitopoulos, Konstantinos
collection PubMed
description BACKGROUND: Carriers with pathogenic variants in MSH2 have increased risk to develop colorectal, endometrium, ovarian, and other types of cancer. The PALB2 is associated with breast, ovarian, pancreatic, and prostate cancer. We describe the case of a 42‐year‐old female diagnosed with endometrial cancer at the age of 42 years with a strong family history of colorectal cancer, which was referred to our private diagnostic laboratory for genetic testing. METHODS: In this study, we performed next‐generation sequencing (NGS) using an amplicon based 26 genes panel. The presence of multi‐exonic copy number variations (CNVs) was investigated by computational analysis and Multiplex Ligation‐dependent Probe Amplification (MLPA). RESULTS: A gross deletion of the genomic region encompassing exons 11–16 of the MSH2 and the loss‐of‐function variant c.757_758delCT, p.(Leu253Ilefs*3) in the PALB2 were identified in the proband. CONCLUSIONS: Multigene analysis using NGS technology allows the identification of pathogenic variants in genes that would normally not be tested based on the patient diagnosis. In our case these results explained not only the personal and/or family history of cancer but also allowed the surveillance for prevention of other cancer types. Moreover, the detection of large genomic rearrangements should be routinely included in hereditary cancer testing.
format Online
Article
Text
id pubmed-7549547
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-75495472020-10-16 Report of a germline double heterozygote in MSH2 and PALB2 Agiannitopoulos, Konstantinos Papadopoulou, Eirini Tsaousis, Georgios N. Pepe, Georgia Kampouri, Stavroula Patsea, Eleni Lypas, George Nasioulas, George Mol Genet Genomic Med Clinical Reports BACKGROUND: Carriers with pathogenic variants in MSH2 have increased risk to develop colorectal, endometrium, ovarian, and other types of cancer. The PALB2 is associated with breast, ovarian, pancreatic, and prostate cancer. We describe the case of a 42‐year‐old female diagnosed with endometrial cancer at the age of 42 years with a strong family history of colorectal cancer, which was referred to our private diagnostic laboratory for genetic testing. METHODS: In this study, we performed next‐generation sequencing (NGS) using an amplicon based 26 genes panel. The presence of multi‐exonic copy number variations (CNVs) was investigated by computational analysis and Multiplex Ligation‐dependent Probe Amplification (MLPA). RESULTS: A gross deletion of the genomic region encompassing exons 11–16 of the MSH2 and the loss‐of‐function variant c.757_758delCT, p.(Leu253Ilefs*3) in the PALB2 were identified in the proband. CONCLUSIONS: Multigene analysis using NGS technology allows the identification of pathogenic variants in genes that would normally not be tested based on the patient diagnosis. In our case these results explained not only the personal and/or family history of cancer but also allowed the surveillance for prevention of other cancer types. Moreover, the detection of large genomic rearrangements should be routinely included in hereditary cancer testing. John Wiley and Sons Inc. 2020-08-27 /pmc/articles/PMC7549547/ /pubmed/32853479 http://dx.doi.org/10.1002/mgg3.1242 Text en © 2020 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Reports
Agiannitopoulos, Konstantinos
Papadopoulou, Eirini
Tsaousis, Georgios N.
Pepe, Georgia
Kampouri, Stavroula
Patsea, Eleni
Lypas, George
Nasioulas, George
Report of a germline double heterozygote in MSH2 and PALB2
title Report of a germline double heterozygote in MSH2 and PALB2
title_full Report of a germline double heterozygote in MSH2 and PALB2
title_fullStr Report of a germline double heterozygote in MSH2 and PALB2
title_full_unstemmed Report of a germline double heterozygote in MSH2 and PALB2
title_short Report of a germline double heterozygote in MSH2 and PALB2
title_sort report of a germline double heterozygote in msh2 and palb2
topic Clinical Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549547/
https://www.ncbi.nlm.nih.gov/pubmed/32853479
http://dx.doi.org/10.1002/mgg3.1242
work_keys_str_mv AT agiannitopouloskonstantinos reportofagermlinedoubleheterozygoteinmsh2andpalb2
AT papadopouloueirini reportofagermlinedoubleheterozygoteinmsh2andpalb2
AT tsaousisgeorgiosn reportofagermlinedoubleheterozygoteinmsh2andpalb2
AT pepegeorgia reportofagermlinedoubleheterozygoteinmsh2andpalb2
AT kampouristavroula reportofagermlinedoubleheterozygoteinmsh2andpalb2
AT patseaeleni reportofagermlinedoubleheterozygoteinmsh2andpalb2
AT lypasgeorge reportofagermlinedoubleheterozygoteinmsh2andpalb2
AT nasioulasgeorge reportofagermlinedoubleheterozygoteinmsh2andpalb2